BACKGROUND: A standard second-line chemotherapy regimen has yet to be defined for patients with gemcitabine (Gem)-refractory advanced pancreatic cancer (PC). PATIENTS AND METHODS: In this multicenter phase II trial, patients with unresectable or metastatic PC who had progressed on single-agent Gem or a Gem-containing regimen received pemetrexed 500 mg/m(2) as a 10-min infusion every 3 weeks until disease progression or occurrence of unacceptable toxicity. The primary end point was the 3-month survival rate. RESULTS: A total of 192 treatment cycles were given to 52 patients. The overall response rate was 3.8% (two partial responses); 10 patients (19.2%) experienced stable disease, nine of them for >12 weeks. At least one CA 19-9 reduction > or =50% occurred in 12 patients (23.1%). The 3-month survival rate was 75% (95% confidence interval 63.2% to 86.8%), the median time to tumor progression was 7 weeks (range 1-62 weeks) and the median overall survival time was 20 weeks (range 1-84 weeks). Grade 3/4 hematological toxic effects included (percent of patients): neutropenia (17.3%), thrombocytopenia (5.8%) and anemia (3.8%). The most frequent non-hematological toxic effects were diarrhea, nausea and stomatitis/pharyngitis (23.1% each). CONCLUSION: Pemetrexed is a safe treatment option with moderate activity in patients with advanced PC after failure of Gem.
BACKGROUND: A standard second-line chemotherapy regimen has yet to be defined for patients with gemcitabine (Gem)-refractory advanced pancreatic cancer (PC). PATIENTS AND METHODS: In this multicenter phase II trial, patients with unresectable or metastatic PC who had progressed on single-agent Gem or a Gem-containing regimen received pemetrexed 500 mg/m(2) as a 10-min infusion every 3 weeks until disease progression or occurrence of unacceptable toxicity. The primary end point was the 3-month survival rate. RESULTS: A total of 192 treatment cycles were given to 52 patients. The overall response rate was 3.8% (two partial responses); 10 patients (19.2%) experienced stable disease, nine of them for >12 weeks. At least one CA 19-9 reduction > or =50% occurred in 12 patients (23.1%). The 3-month survival rate was 75% (95% confidence interval 63.2% to 86.8%), the median time to tumor progression was 7 weeks (range 1-62 weeks) and the median overall survival time was 20 weeks (range 1-84 weeks). Grade 3/4 hematological toxic effects included (percent of patients): neutropenia (17.3%), thrombocytopenia (5.8%) and anemia (3.8%). The most frequent non-hematological toxic effects were diarrhea, nausea and stomatitis/pharyngitis (23.1% each). CONCLUSION:Pemetrexed is a safe treatment option with moderate activity in patients with advanced PC after failure of Gem.
Authors: Hyun Jung Kim; Jina Yun; Han Jo Kim; Kyoung Ha Kim; Se Hyung Kim; Tae Hoon Lee; Sang-Cheol Lee; Sang Byung Bae; Chan Kyu Kim; Nam Su Lee; Jong Ho Moon; Sang Heum Park; Kyu Taek Lee; Seong Kyu Park; Jong-Ho Won; Hee Sook Park; Dae Sik Hong Journal: Oncol Lett Date: 2012-03-08 Impact factor: 2.967
Authors: György Bodoky; Constanta Timcheva; David Robert Spigel; Phillip Joseph La Stella; Tudor Eliade Ciuleanu; G Pover; N C Tebbutt Journal: Invest New Drugs Date: 2011-05-19 Impact factor: 3.850
Authors: Brian M Wolpin; Aram F Hezel; Thomas Abrams; Lawrence S Blaszkowsky; Jeffrey A Meyerhardt; Jennifer A Chan; Peter C Enzinger; Brittany Allen; Jeffrey W Clark; David P Ryan; Charles S Fuchs Journal: J Clin Oncol Date: 2008-12-01 Impact factor: 44.544
Authors: Andrew L Coveler; Andrew H Ko; Daniel V T Catenacci; Daniel Von Hoff; Carlos Becerra; Nancy C Whiting; Jing Yang; Brian Wolpin Journal: Invest New Drugs Date: 2016-03-18 Impact factor: 3.850